NCT04756141View on ClinicalTrials.gov

CGM Use in COVID19 Patients (Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2))

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 3, 2021

Primary Completion Date

August 24, 2022

Study Completion Date

August 24, 2022

Conditions
Diabetes MellitusCovid19
Interventions
DEVICE

Continuous Glucose Monitor (CGM)

A CGM will be placed on patients with diabetes mellitus and COVID-19 infection and interstitial glucose will be monitored continuously while the patients are in the hospital.

Trial Locations (1)

32224

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT04756141 - CGM Use in COVID19 Patients (Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)) | Biotech Hunter | Biotech Hunter